Fig. 4. Forest plot of overall survival by subgroup after PSM.
AI aromatase inhibitor; Dx diagnosis; ECOG PS Eastern Cooperative Oncology Group performance status; ND not documented; PAL palbociclib; PSM propensity score matching. *Bone-only disease was defined as metastatic disease in the bone only. †Visceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.